TransCelerate BioPharma Launches Two New Global Initiatives That Aim to Improve Clinical Research

TransCelerate BioPharma Launches Two New Global Initiatives That Aim to Improve Clinical Research

April 08, 2015 09:30 AM Eastern Daylight Time

PHILADELPHIA--()--TransCelerate BioPharma Inc. today announced that it has established two new global initiatives which will accelerate and enhance clinical trials. Both initiatives - Placebo / Standard of Care Data Sharing and Electronic Labels for Clinical Trials (e-Labels), are made possible through the collaboration of participating Member Companies. They aim to create solutions that will have a direct impact on patients, sponsors and investigative sites.

The Placebo / Standard of Care Data Sharing Initiative has the potential to create a framework for data sharing that offers the potential to reduce the patient population needed to be enrolled in a clinical trial, as it intends to allow for the leverage of data from previous studies respecting boundaries of informed consent. It would thereby decrease the time spent on cumulative trial execution, and assists in acceleration of new therapies to patients. It also offers the potential for more rapid understanding of safety signals to better manage patient safety during clinical trials, as well as identify statistical techniques that may deliver more accurate study design and statistical power calculations.

Ulo Palm, MD, PhD, Senior Vice President, Head of Global Brands Drug Development Operations at Actavis, and TransCelerate Executive Sponsor for the initiative states, "The TransCelerate solution has the potential to change the way clinical trials are designed, planned and executed. Providing this platform to Member Company biostatisticians may lead to improved protocol development, reduction in protocol amendments and a better understanding of disease models to identify the right targets, including rare disease models."

Ed Bowen, Senior Director, Translational and Bioinformatics at Pfizer and the lead of this initiative, echoes Dr. Palm's enthusiasm on the solution, noting, "Sharing placebo and standard of care data is good for patients and good for our R&D organizations. Data re-use is especially important in rare diseases where patient populations are small. We want to maximize the value from the data generated from a patient participating in a clinical trial, as well as the R&D investment. We strongly desire to speed the delivery of innovative therapies to underserved patients. Pooling this data among TransCelerate Member Companies has the potential to be powerful and is representative of TransCelerate's overall mission, which is to provide efficient, effective and high quality outcomes for the larger clinical ecosystem through Member Company collaboration."

The e-Labels Initiative will support TransCelerate Member Companies in establishing an innovative information channel: Electronic Labels (e-Labels). This initiative will work to enhance label utility for patients, provide more consistent labeling approaches for sites and offers the potential to reduce clinical labeling timelines and provides cost efficiencies for sponsors. The Initiative, in collaboration with Regulatory Agencies, will develop guidance to facilitate implementation of e-Labeling.

Craig Lipset, Head of Clinical Innovation at Pfizer, and Executive Sponsor of the TransCelerate e-Labels Initiative, states, "This effort aims to make product information more accessible to patients and to permit deeper engagement during the clinical trial process."

"The time is right for pharma companies to embrace e-labeling as a critical component to their clinical supply chain strategy," notes Terry Walsh, Head of Comparator Strategy and Planning at GlaxoSmithKline and the lead of this initiative. "The TransCelerate e-label Initiative is aligned with our primary goals of collaborating with critical stakeholders, challenging inefficiencies and driving value into the clinical trial landscape."

About TransCelerate BioPharma Inc.

TransCelerate BioPharma Inc. is a non-profit organization dedicated to improving the health of people around the world by accelerating and enhancing the research and development (R&D) of innovative new therapies. The organizations' mission is to collaborate across the global biopharmaceutical R&D community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines. TransCelerate evolved from discussions at various forums for executive R&D leadership to debate current issues facing the industry, and examine solutions for addressing common challenges. The founding member companies are AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, the Roche Group, and Sanofi. Additional members that have joined since the inception of TransCelerate include Actavis, Allergan, Inc., Astellas Pharma Inc., Biogen, Cubist Pharmaceuticals, EMD Serono, Inc. (a subsidiary of Merck KGaA, Darmstadt, Germany), Medgenics, Inc., Merck & Co., Inc., Novo Nordisk A/S, Shionogi & Co., Ltd. and UCB.

Membership in TransCelerate is open to pharmaceutical and biotechnology companies with Research & Development operations. Executive offices are located in Philadelphia, PA. For more information, please visit


Bliss Integrated Communication
Vicky Aguiar, 212-584-5470
[email protected]


Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.